Critical appraisal:Van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, et al 2014 2

From Cancer Guidelines Wiki

Risk of bias assessment: cohort study

Subject selection
"New technology" group
Selected group
Comparison group
Selected group
Comparability of groups on demographic characteristics and clinical features
Not comparable but adjusted analysis used
Measurement of outcomes
Outcome measures blind to technology used
No, but objective measures used
Same method of measurement used across comparison groups
Yes
Completeness of follow-up
Was follow-up complete and were all patients included in the analysis?
Yes (follow-up >95%) or survival analysis using all patients
Overall risk of bias
Moderate risk of bias Additional comments: Please replace this text and include any additional comments in regards to your quality rating


Jutta's tick icon.png This appraisal has been completed.


Article
van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, et al. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. Ann Surg Oncol 2014 Sep;21(9):3108-16 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24802907.
Assigned to
User:Lyndal.alchin
Topic area
Guidelines:Melanoma
Clinical question
Form
Form:Quality appraisal cohort


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment